Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.

ABSTRACT:

Background

AURA study reported 61% objective response rate and progression-free survival of 9.6 months with osimertinib in patients with EGFR/T790M+ non-small cell lung cancer. Due to lack of real-world data, we proposed this study to describe the experience with osimertinib in Spain.

Methods

Post-authorization, non-interventional Special Use Medication Program, multicenter, retrospective study in advanced EGFR/T790M+ non-small cell lung cancer. One hundred-fifty five patients were enrolled (August 2016-December 2018) from 30 sites.

Primary objective

progression-free survival. Secondary objectives: toxicity profile, objective response rate, and use of health service resources.

Results

70% women, median age 66. 63.9% were non-smokers and 99% had adenocarcinoma.

SUBMITTER: Provencio M 

PROVIDER: S-EPMC7937205 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature